Previous Article | Next Article ![]()
Journal of Virology, April 1999, p. 2893-2900, Vol. 73, No. 4
Laboratory of Biochemistry and Genetics,
National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health, Bethesda, Maryland 20892-0830
Received 20 October 1998/Accepted 14 December 1998
We mapped and cloned SKI7, a gene that negatively
controls the copy number of L-A and M double-stranded RNA viruses in
Saccharomyces cerevisiae. We found that it encodes a
nonessential 747-residue protein with similarities to two translation
factors, Hbs1p and EF1-
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
The Ski7 Antiviral Protein Is an EF1-
Homolog
That Blocks Expression of Non-Poly(A) mRNA in
Saccharomyces cerevisiae


. The ski7 mutant was
hypersensitive to hygromycin B, a result also suggesting a role in
translation. The SKI7 product repressed the expression of
nonpolyadenylated [non-poly(A)] mRNAs, whether capped or uncapped,
thus explaining why Ski7p inhibits the propagation of the yeast
viruses, whose mRNAs lack poly(A). The dependence of the Ski7p effect
on 3' RNA structures motivated a study of the expression of capped
non-poly(A) luciferase mRNAs containing 3' untranslated regions
(3'UTRs) differing in length. In a wild-type strain, increasing the
length of the 3'UTR increased luciferase expression due to both
increased rates and duration of translation. Overexpression of Ski7p
efficiently cured the satellite virus M2 due to a
twofold-increased repression of non-poly(A) mRNA expression. Our
experiments showed that Ski7p is part of the Ski2p-Ski3p-Ski8p antiviral system because a single ski7 mutation derepresses
the expression of non-poly(A) mRNA as much as a quadruple ski2
ski3 ski7 ski8 mutation, and the effect of the overexpression of
Ski7p is not obtained unless other SKI genes are
functional. ski1/xrn1
ski2
and ski1/xrn1
ski7
mutants were viable but temperature sensitive for growth.
*
Corresponding author. Mailing address: Bldg. 8, Room
225, NIH, 8 Center Dr. MSC 0830, Bethesda, MD 20892-0830. Phone: (301) 496-3452. Fax: (301) 402-0240. E-mail:
wickner{at}helix.nih.gov.
Present address: Institut de Biologie Physico-Chimique UPR9073,
75005 Paris, France.
Present address: Technology Development and Commercialization
Branch, National Cancer Institute, Rockville, MD 20852.
§
Present address: Center for Biologics Evaluation and Research, Food
and Drug Administration, Bethesda, MD 20892.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|